The global hyperhidrosis treatment market size was valued at USD 1,611.31 million in 2022. It is projected to reach USD 2,307.33 million by 2031, growing at a CAGR of 4.07% during the forecast period (2023-2031).
Hyperhidrosis is excessive sweating that is not always related to heat or exercise. Excessive perspiration can cause leaks in clothing and wet palms. Excessive sweating triggers social anxiety and embarrassment and can ruin a person's day. Hyperhidrosis is characterized by excessive sweating, which can affect the chest, lower limbs, belly, back, and inguinal areas and the palms, soles, armpits, and face.Increasing rates of secondary hyperhidrosis are linked to sedentary lifestyles, poor diets, and alcohol consumption, which can lead to several diseases, such as hypoglycemia, hyperthyroidism, and anxiety. The global market for hyperhidrosis treatments is divided into segments based on type, treatment, distribution method, and geography.
The disease is called secondary hyperhidrosis when a medical problem involves excessive sweating. The less frequent ailment is more likely to be the source of excessive bodily perspiration. The increase in secondary hyperhidrosis prevalence is fueling the need for secondary hyperhidrosis therapy, boosting the market. According to the 2020 International Hyperhidrosis Society, 365 million individuals worldwide have secondary hyperhidrosis and excessive sweating, or approximately 5% of the global population. Unlike primary hyperhidrosis, which usually develops in childhood or adolescence, excessive sweating typically begins in maturity. The adult population is, therefore, more likely to experience chronic illnesses. The prevalence of secondary hyperhidrosis is rising quickly due to the adult population's substantial growth rate.
Additionally, according to the publication, there will be 643 million individuals worldwide living with diabetes by 2030 and 783 million by 2045. According to these figures, the incidence of secondary hyperhidrosis would rise as diabetes mellitus rises. Therefore, it is anticipated that the causes mentioned above will increase demand for hyperhidrosis treatments, contributing to the overall expansion of the market under study.
The short-term nature of the treatments for hyperhidrosis limits the demand for hyperhidrosis treatment. For instance, according to the 2022 American Academy of Dermatology Association, surgical procedures include; Curettage (scrape out), an excision (cut out sweat glands), and Liposuction (remove with suction).
Another operation used to treat hyperhidrosis, which raises the risk of infection and a condition known as compensatory sweating, is a sympatheticectomy. Additionally, according to the 2022 American Academy of Dermatology Association, a chemical in the body that stimulates the sweat glands is momentarily blocked by a botulinum toxin injection. Most patients see results four to five days after receiving treatment.
Additionally, according to the 2022 SAFELipo, BOTOX injections shut down sweat glands. Compared to thermal liposuction, it is safer. BOTOX is a quick fix; repeating the shots is necessary to keep the effects. A sympathectomy may also cause damage to the nerves that connect the brain and eyes, severely low blood pressure, irregular heartbeat, and an inability to tolerate heat, according to the American Academy of Dermatology Association of 2022. Therefore, the studied segment is anticipated to experience a negative impact during the projection period due to the short-term results of the cosmetic and therapeutic treatments.
The market under study is expanding due to the increased investments made by market participants in R&D. Several industry participants are investing in R&D to create efficient therapies and items used to treat hyperhidrosis. 5% sofpironium bromide gel will soon be available in Japan under the brand name ECCLOCK for the daily treatment of primary axillary (underarm) hyperhidrosis, according to Brickell Biotech Inc., a clinical-stage pharmaceutical company specializing in the development of novel and distinctive prescription therapeutics for the treatment of disabling skin diseases. Positive findings from a Phase 1 POC clinical study of DMT410 (DMT310 plus botulinum toxin (BTX)) for the treatment of primary axillary hyperhidrosis were released by Dermata Therapeutics LLC. These findings support Dermata's recently created combination regimen, DMT400, which uses DMT310 sponge powder to deliver biologics to the dermis topically. The market is therefore anticipated to experience strong growth over the forecast period due to the factors above.
Based on treatment type, the global hyperhidrosis treatment market is bifurcated into topical treatments, surgical treatments, botulin toxin a, iontophoresis, laser treatments, and other treatment types.
The topical treatments segment is the highest contributor to the market and is estimated to grow at a CAGR of 4.05% during the forecast period. Astringent substances, local anesthetics, and aluminum chloride are all topical therapies for hyperhidrosis. The FDA has approved topical anticholinergic wipes. The general populace of industrialized nations utilizes over-the-counter antiperspirants to regulate underarm sweating and odor for cosmetic reasons. Patients with moderate to severe hyperhidrosis, however, need more aggressive care. People with hyperhidrosis have a much lower quality of life than those with psoriasis or atopic dermatitis. A mechanical barrier that stops sweating is created when aluminum chloride is applied topically and reacts with the proteins in the sweat duct.
CertainDri and Maxim's antiperspirant are two of the top 10 topical therapies for hyperhidrosis currently on the market. ZeroSweat can halt excessive sweating for more than a week with just one application. A three-step program from Duradry can help one manage excessive perspiration. Drysol can be applied to the groin region, hands, feet, face, back, and skin folds. Antiperspirant with prescription strength Xerac AC helps manage hyperhidrosis. Carpe lotion aids in the daily management of hyperhidrosis symptoms. Ducray absorbs scents brought on by bacteria breaking down sweat, A prescription cloth towelette called QBREXZA is used to treat extreme underarm sweating. At the same time, SweatBlock is a clinical-strength antiperspirant wipe for treating hyperhidrosis.
The procedure for sympathetic nerves has developed from an open to an endoscopic operation. This prevents symptoms from being brought on by brain signals entering the nerve. Depending on which portion of the nerve is treated, the treatment is either an endoscopic thoracic sympathectomy (ETS) or an endoscopic lumbar sympathectomy. It has been challenging to adopt surgical intervention for compensatory hyperhidrosis because of its uncertain outcomes and adverse effects. Numerous clinics and hospitals provide this procedure. For instance, Cedars-Sinai has years of experience using surgery to treat hyperhidrosis. The abundance of clinics and outpatient facilities and patients' willingness to adjust their treatments widely are driving the market's expansion.
Based on disease type, the global hyperhidrosis treatment market is bifurcated into primary focal hyperhidrosis and secondary generalized hyperhidrosis.
The primary focal hyperhidrosis segment owns the highest market and is estimated to grow at a CAGR of 4.19% during the forecast period. Underarms, feet, and palms are just a few of the body parts that suffer from primary hyperhidrosis, which is a disorder that causes excessive sweating in those places. Primary hyperhidrosis is excessive sweating bilaterally symmetric, unrelated to other underlying disorders, and affects the axillae, palms, soles, or craniofacial region. Primary hyperhidrosis, which usually manifests in childhood and gets worse with puberty, especially in women, is typically inherited. Affected people may react more intensely to stimuli that can make them sweat, such as anxiety, pain, exercise, stress, caffeine, and nicotine. According to the Primary Care Dermatology Society (PCDS) 2021, 1% of people have primary or focused hyperhidrosis, which happens on its own and has no additional symptoms. Approximately one-third of cases involve a familial history. Most patients will require treatment for the remainder of their lives because the disease has a chronic course.
A different medical condition or a drug side effect brings on a type of excessive sweating called secondary generalized hyperhidrosis. Infections, neoplasia, metabolic and endocrine abnormalities, high catecholamine states, medication therapy, and neurological problems are all associated with it. Contrary to primary focal hyperhidrosis, secondary hyperhidrosis results in sweating in more extensive or other body sections (described as generalized areas). The kind is less typical. It is more likely to result in excessive bodily perspiration. Excessive sweating can be brought on by diabetes, menopause, hot flashes, thyroid issues, low blood sugar, some cancers, heart attacks, nervous system illnesses, hyperactive thyroid, Parkinson's disease, spinal cord damage, stroke, tuberculosis or other infections, carcinoid syndrome, and anxiety.
Disrupting the autonomic nervous system or neurological conditions like Parkinson's disease or spinal cord damage can also cause generalized hyperhidrosis. People with secondary generalized hyperhidrosis frequently experience sleep-related sweating symptoms. Generalized hyperhidrosis is more prone to occur in adults. Investigation and treatment of the underlying problem are the initial steps in management since widespread hyperhidrosis typically results from a medical condition, which is why they are essential.
The global hyperhidrosis treatment market is bifurcated into four regions: North America, Europe, Asia-Pacific, and LAMEA.
North America is the most significant revenue contributor and is expected to grow at a CAGR of 3.46% during the forecast period. American companies significantly dominate the market for treating hyperhidrosis. The market is driven by the rising prevalence of primary hyperhidrosis, cancer, cardiovascular diseases that worsen secondary hyperhidrosis, technological improvements, and significant market participants in the nation. The adoption of treatment in the country will expand due to the high prevalence of primary and secondary hyperhidrosis. For instance, a study titled "Hyperhidrosis," published in October 2021 in the U.S. National Library of Medicine, indicated that it affects about 3% of the U.S. population and is most prevalent in people between the ages of 20 and 60. Due to its high incidence, the nation adopted more treatments, including over-the-counter 20% aluminum chloride hexahydrate. This pervasiveness will drive more demand for the product, leading to faster market growth. Nine hundred and fifty thousand Canadians, or about three percent of the population, suffered from hyperhidrosis in 2022, with another three hundred thousand experiencing severe cases.
Additionally, research has found that only 38% of hyperhidrosis individuals discuss their illness with a medical expert. Secondary hyperhidrosis may be brought on by cancer, infections, endocrine/metabolic problems, cardiovascular illness, respiratory disease, neurologic disorders, psychiatric disorders, or drugs, according to research released by the Canadian Skin Patient Alliance in February 2022. As a result, the market for Canadian hyperhidrosis treatments is anticipated to develop due to the rise in chronic conditions like cancer. For instance, one of the elements contributing to the segment's growth is the rise in blood-related illnesses.
Europe is expected to grow at a CAGR of 4.28% during the forecast period. Global pharmaceutical and medical device businesses with a significant presence in Germany are developing treatments for hyperhidrosis. Additionally, the rise in primary and secondary hyperhidrosis prevalence and the expansion of hyperhidrosis-related research and development are anticipated to fuel market expansion throughout the projected period. 17.9% of people worldwide had hyperhidrosis, comparable to research done in Germany, where the prevalence was 16.3%. The market for hyperhidrosis treatments will expand due to the rising prevalence in Germany and the greater treatment uptake there. The expansion of this market in Germany is also anticipated to be fueled by an increase in investments made by major market players in research and development to create medicines to treat hyperhidrosis.
In the United Kingdom,the market of interest is proliferating because of the advanced healthcare system and the developing healthcare company. In addition, it is anticipated that the prevalence of diabetes in the United Kingdom, the burden of hyperhidrosis, and research into the condition will all increase in the coming years. De Montfort University (DMU), Leicester, concentrated on researching the condition known as hyperhidrosis to find a long-term cure for patients. To increase financing for research into novel and improved treatments for hyperhidrosis, Dr. Louise Dunford of DMU's research team promoted awareness of the condition. Additionally, a rise in the number of hyperhidrosis-related product introductions in the United Kingdom is anticipated to fuel market expansion.
China is one of the regions with the quickest growth rate in the market for treating hyperhidrosis. The high prevalence of hyperhidrosis in the nation is the primary driver of the market's expansion. Hyperhidrosis (HH) is widespread in the Chinese population over 65, according to a study published in 2021 in the National Library of Medicine titled "The Association Between Hyperhidrosis and Dementia: A Community-Based Research." It can raise the chance of dementia in the elderly, especially in DLB. It's critical to raise dermatologists' and neurologists' awareness of HH. A greater demand for therapeutic solutions would result from increased awareness, accelerating market expansion.
The Indian healthcare system has witnessed improvement with the developing economy. The burden of secondary hyperhidrosis is growing in the nation due to the rise in the prevalence of CVDs and the growing awareness of and demand for high-quality healthcare. For instance, diabetes has become a problem in India, with a majority of 8.8% in the age group of 20 and 70 years, according to January 2020 research titled "Cardiovascular disease in India: A 360-degree perspective." Fast urbanization, globalization, sedentary lifestyles, bad diets, overweight and obesity, cigarette use, and rising life expectancy have all been related to the increased prevalence of non-communicable diseases like diabetes. Due to the high prevalence of diabetes, secondary hyperhidrosis is predicted to become more common in India, fueling market expansion.
In the Middle East and Africa, Saudi Arabia and the United Arab Emirates are two of the most developed economies with robust healthcare systems. This creates a significant opportunity for adopting the hyperhidrosis treatment market in the healthcare system, which is anticipated to propel this market's growth in GCC nations. In both the short and long term, bilateral endoscopic thoracic sympathectomy (BETS) was a successful option for improving patients' quality of life and treating upper limb hyperhidrosis. Increased adoption of the hyperhidrosis treatment in GCC countries will result from the rising good outcomes of BETS in hyperhidrosis, fueling this region's hyperhidrosis market expansion. Israel, Egypt, and other Middle Eastern nations all have high rates of cardiovascular disease. For instance, heart disease is Israel's second leading cause of mortality after cancer, according to the Ministry of Health's State of Israel 2020 report. Due to the rising use of hyperhidrosis therapy in cardiovascular illnesses, which is driving the expansion of hyperhidrosis treatment in this region, the high prevalence of diseases benefits market growth.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|